Drug or Drug Class

Formulary Decision

Comments

Restricted to oncology for the treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose or those with early onset (< 96 hrs) severe or lifethreatening toxicity from these agents.

Available to hospital within 24 hrs.

Automatic interchange to Tussionex PennKinetic Liquid.

Tuzistra XR 10 mL is equivalent to Tussionex 3 mL.

Physicians must undergo a special training program and be certified to prescribe Addyi.

Therapy should not be continued in the hospital.

Clinical trials show no evidence of adverse events following abrupt discontinuation.

Due to a multi-state outbreak of infections caused by Burkholderia cepacia complex, the CDC has recommended clinicians avoid use of any liquid docusate products in all patients.

Previously, the CDC had recommended avoiding in immunocompromised or critically ill patients.

Upon receipt of a physician’s order, approved clinical staff may initiate IV access and infuse up to liter of IV fluids as ordered prior to pharmacist verification.

A risk analysis completed on July 25, 2016 led to the conclusion that this was a low risk process.

Policies updated to specify loading doses and as needed bolus doses of heparin administered into the dialysis circuit.

A risk analysis completed on July 26, 2016 discussing storage and use of heparin during dialysis led to the conclusion this was a low risk process.

The policy outlines dosing, dispensing, and administration restrictions and requirements.

CRNPs, PAs, or medical residents/interns may not order IV hypertonic saline. Nephrology must be consulted for follow-up of hyponatremia management in adult patients initiated on hypertonic saline.